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Background: Malignant Pleural Mesothelioma (MPM) is an aggressive tumor arising from mesothelial cells lining
the pleural cavities characterized by resistance to standard therapies. Most of the molecular steps responsible for
pleural transformation remain unclear; however, several growth factor signaling cascades are known to be altered
during MPM onset and progression. Transducers of these pathways, such as PIK3CA-mTOR-AKT, MAPK, and
ezrin/radixin/moesin (ERM) could therefore be exploited as possible targets for pharmacological intervention.
This study aimed to identify ‘druggable’ pathways in MPM and to formulate a targeted approach based on the
use of commercially available molecules, such as the multikinase inhibitor sorafenib and the mTOR inhibitor everolimus.
Methods: We planned a triple approach based on: i) analysis of immunophenotypes and mutational profiles in a
cohort of thoracoscopic MPM samples, ii) in vitro pharmacological assays, ii) in vivo therapeutic approaches on MPM
xenografts. No mutations were found in ‘hot spot’ regions of the mTOR upstream genes (e.g. EGFR, KRAS and PIK3CA).
Results: Phosphorylated mTOR and ERM were specifically overexpressed in the analyzed MPM samples. Sorafenib and
everolimus combination was effective in mTOR and ERM blockade; exerted synergistic effects on the inhibition of MPM
cell proliferation; triggered ROS production and consequent AMPK-p38 mediated-apoptosis. The antitumor activity was
displayed when orally administered to MPM-bearing NOD/SCID mice.
Conclusions: ERM and mTOR pathways are activated in MPM and ‘druggable’ by a combination of sorafenib and
everolimus. Combination therapy is a promising therapeutic strategy against MPM.
Keywords: mTOR, ezrin, Malignant pleural mesothelioma, Targeted therapy, Preclinical models, Apoptosis, Reactive
oxygen species, Translational oncologyBackground
Malignant Pleural Mesothelioma (MPM) is an aggressive
tumor characterized by poor prognosis and by continu-
ously increasing incidence due to widespread exposure
to asbestos [1]. There is still no effective therapeutic* Correspondence: g.stella@smatteo.pv.it
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unless otherwise stated.regimen for MPM; as a consequence, the median sur-
vival is approximately one year [2]. This tumor therefore
represents an unsolved health problem with an urgent
medical need.
MPM is histologically classified as (i) epithelial (50-70%
of cases), (ii) mesenchymal or sarcomatous (7-20% of
cases), and (iii) mixed or biphasic (20-35% of cases) [3].
Although most of the molecular steps driving MPM onset
and progression are still unclear, several signaling path-
ways are known to be altered in this disease [4]. Among
them, activated phosphatidyl inositol-3-kinase-mammalian
target of rapamycin-protein kinase B (PIK3CA-mTOR-tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[7] cascades have been documented as playing a relevant
role in MPM progression, being further associated to a
worst prognosis [8]. However, small molecule inhibitors of
the upstream tyrosine kinase receptors (e.g. the epithelial
growth factor receptor, EGFR), although successfully used
for the treatment of different epithelial tumors, are not ef-
fective against MPM [9,10]. A better understanding of
MPM biology is therefore a clear priority both for the
assessment of targeted agents, and for the selection of pa-
tients that are likely to achieve clinical benefit. We here re-
port a deep investigation of the main oncogenic pathways
that could be involved in MPM with particular interest in
mTOR pathway. Moreover, unlike many other cancers,
MPM progression does not generally impact distant or-
gans, but normally affects the organs around the pleura,
mainly the lungs on the side of the body in which the ori-
ginal tumor was found and the abdomen and peritoneal
cavity. From this basis, we hypothesized that activation of
ezrin-radixin-moesin (ERM) members of the cell cortex
involved in cell adhesion, cell motility, and signal trans-
duction [11,12] could have a role in inducing the peculiar
pattern of ‘local spread’ in MPM. Overall this approach
was followed by the design and testing of therapeutic
strategies targeting the mTOR and the ERM signaling cas-
cade. mTOR is a kinase of the PIK3CA-related family act-
ing as key regulator of the switch between catabolic and
anabolic metabolism. In the last decade, this transducer
has emerged as a therapeutic target for a number of dis-
eases, among which cancer [13]. We therefore reasoned
that molecular lesions affecting the mTOR signaling path-
way could be targettable by clinical grade, mTOR-specific
inhibitors. The plasma membrane-cytoskeleton linker pro-
tein ezrin, member of ERM family, plays a crucial role in
the proliferation and metastatization of several aggressive
tumors, being sarcomas the most investigated [14,15].
Ezrin is activated by phosphorylation during cell growth
and motility in both normal and tumor-derived cells [16].
We have previously demonstrated for the first time that
this pathway can be therapeutically targeted in preclinical
models of osteosarcomas, by treatment with the multi-
kinase inhibitor sorafenib. In particular this drug to inhibits
the phosphorylation of ERM in their critical sites (Thr567
on ezrin; Thr564 on radixin and Thr558 on moesin) [17].
However, so far the role of ERM proteins in MPM has
never been investigated.
To identify novel, molecularly-targeted therapeutic
strategies immediately available for clinical use in MPM
management, we here explored the in vitro and in vivo
anti-tumor effects of the mTOR specific inhibitor
everolimus in combination with sorafenib. Although
both drugs are already in phase II clinical trial for
MPM, no data are available concerning the effects of
the association.In this work, for the first time we show that ERM pro-
teins are activated in MPM and ezrin in particular has a
role in cell proliferation and migration of MPM cells.
Moreover, we demonstrated that sorafenib and everolimus
combination has antitumor activity in MPM preclinical
models in vitro and in vivo.
Methods
MPM sample selection
We selected and analyzed 30 MPM samples (10 cases
for each histological subtype) derived from medical
thoracoscopy from a cohort of patients aged ≥18 years
who referred to the Pneumology Department at Fonda-
zione IRCCS Policlinico San Matteo, Pavia, Italy. The
histopathological analysis of sections from formalin-fixed,
paraffin-embedded (FFPE) specimens was performed at
the Pathology Unit of the same hospital. Complete clinical
data of each patient object of this study are listed in
Additional file 1: Table S1.
The expression of phospho-m-TOR (P-mTOR) and
phospho-ERM (P-ERM) proteins was investigated by im-
munohistochemistry, as described in the Additional file 1.
Tumor DNA was extracted from each FFPE sample with
a commercial kit following the manufacturer’s recommen-
dations; in all cases the histological sections contained
more than 80% tumour tissues and less than 5% necrosis.
We evaluated the mutational profile of ‘hot spot’ regions
of three oncogenes frequently mutated in solid cancers:
KRAS (exon 2), EGFR (exons 18-19-20-21) and PIK3CA
(exons 9–20), as described in the Additional file 1.
MPM cell culture, drugs and reagents
The human MPM cell lines MSTO-211H, NCI-H28,
NCI-H2052 and NCI-H226 were obtained from the
American Type Culture Collection (Rockville, MD).
Ist-Mes-1 and Ist-Mes-2 were obtained from Genoa
Institute Culture Collection. Two cell lines (MM001,
MM002) were established in our laboratory from
pleural effusions derived from two patients diagnosed
with MPM and characterized by routine pathology
evaluation. The procedure was approved by the local
Ethical Commission and each enrolled patient gave written
informed consent before enrolment (Comitato di Bioetica,
Fondazione IRCCS Policlinico San Matteo, approval num-
bers: protocol #20090002344; procedure #20090019080;
date of approval: June 3rd, 2009). MES-MM98 cell line
was from the biobank of the Hospital of Alessandria
(Pathology Unit), and previously described [18]. Cells
culture protocols are described in the Additional file 1.
Sorafenib (SOR) and everolimus (EV) (Sequoia Research
Product, UK) stock solutions were prepared in DMSO
and stored at −20°C. Control and human ezrin-specific
siRNA were purchased from Ambion (Life Technologies
Italia, Monza MB).
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Each MPM cell line was incubated with scalar doses of
sorafenib (from 10 μM to 0.625 μM), everolimus (from
2 μM to 12.5 nM), or their constant combination. Prolif-
eration, migration, and colony formation capacity were
evaluated to assess differences between (i) treated and
untreated cells, and (ii) control and human ezrin-specific
siRNA-transduced cells. Details about the in vitro assays
are listed in the Additional file 1.
To analyze the activation of signal transduction cas-
cades, MPM cells (80% confluence) were treated for 24 h
with EV (100 nM) or SOR (5 μM), alone or in combin-
ation, or left untreated. Western Blot analysis is described
in the Additional file 1.
The impact of cell treatment on apoptosis, cell cycle,
radical oxygen species (ROS) production was analyzed
by assays based on flow cytometry as described in the
Additional file 1.
Mice xenograft models
Non-obese diabetic/severe combined immunodeficient
(NOD/SCID) female mice (Charles River, Milan, Italy) were
breed, maintained in cage microinsulators, and handled
under sterile conditions at the animal facility of the Insti-
tute for Cancer Research and Treatment (Candiolo, Italy).
Animal manipulation was approved by the Institute’s
Ethical Commission and by the Italian Ministry of
Health. In three independent experiments, 24 female
mice (4–6 weeks old) were injected subcutaneously
(s.c.) into the right flank with 106 MSTO-211H cells in
growth factor-reduced BD Matrigel basement membrane
matrix (BD Biosciences, San Jose, CA). When xenografts
were established at about 100 mm3 after 5 weeks, animals
were divided into 4 groups and were treated daily by oral
gavage with either sorafenib (5 mg/kg/die), everolimus
(1 mg/kg/die), their combination (sorafenib 5 mg/kg/die +
everolimus 1 mg/kg/die), or vehicle alone for 4 weeks
before the sacrifice (see Additional file 1).
Ethics statement
The procedure was approved by local Ethical Commission
and each enrolled patient gave written informed consent
before enrolment (Comitato di Bioetica, Fondazione
IRCCS Policlinico San Matteo, approval numbers: proto-
col #20090002344; procedure # 20090019080; date of ap-
proval: June 3rd, 2009). Mice experiments were approved
by the Ethical Commission of the Institute for Cancer
Research and Treatment (Candiolo, Torino, Italy), and of
the Italian Ministry of Health.
Results
mTOR and ERM are activated in human MPM
Of the 30 mesothelioma specimens analyzed, 10 exhibited
epithelioid, 10 biphasic and 10 sarcomatous histology.This cohort analyzed in the work derived by selection of
10 MPM cases of each major histological subtype and,
thus, does not reflect the biology of MPM. All the patients
referred occupational or environmental exposure to as-
bestos; the vast majority (25 out of 30) of the evaluated
patients were previous and current smokers. Five out of
the 30 patients were females. The median age at diag-
nosis was 67 years and the median overall survival (OS)
was 15.9 months, coherent with already published data.
We evaluated the expression of phosphorylated mTOR
(P-mTOR) and ERM (P-ERM) by immunohistochemis-
try. P-mTOR was expressed in most cases (83%) in
both sarcomatous and epithelial subtypes. P-ERM was
present at moderate-high levels in almost all samples
(93%), and was not associated to a particular histotype
(Additional file 1: Table S1). Staining obtained in repre-
sentative cases of epithelioid and sarcomatous MPM is
shown in Figure 1. These results were confirmed by
semi-quantitative evaluation (Additional file 1: Table S1).
Within the limit of the cohort analyzed, the correlation
between OS and intensity of P-mTOR seems to be not sig-
nificant; whereas P-ERM really positive (+++) patients dis-
play a higher OS (Additional file 2: Figure S1). The
analysis of mutational profiles in the ‘hot spot’ regions of
EGFR (exons 18–21), KRAS (exon 2), and PIK3CA (exons
9 and 20) genes revealed no somatic mutations in MPM
samples (Additional file 1: Table S1).
Sorafenib and everolimus inhibit mTOR, ERK1/2 MAPK in
MPM cell lines
The activation of the mTOR and ERK1/2 MAPK signal-
ling cascades plays a fundamental role in cancer progres-
sion. Having shown that MPM samples expressed high
amounts of phosphorylated mTOR (Figure 1), we inves-
tigated the druggability of these pathways by everolimus
and/or sorafenib in preclinical models of MPM. As a
first step in the design of a molecularly-targeted therapy,
we treated seven different MPM cell lines with sorafenib
and everolimus for 24 hours, followed by western blot
evaluation of phosphorylated protein transducers. We
confirmed a decreased phosphorylation of mTOR/
4EBP1/p70S6K and MAPK/p90RSK signalling cascades
in all cell lines treated with everolimus or sorafenib, re-
spectively. As reported for other tumor types [19], we
observed that everolimus induces AKT activation: this
effect may be a result from a negative feedback loops in-
volving p70S6K. Figure 2 show the results obtain in
MES-MM98 as representative of 7 tested cell lines.
Sorafenib and everolimus inhibit ERM phosphorylation
and migration of MPM cell lines
We have also shown that ERM proteins are broadly phos-
phorylated in MPM samples (Figure 1). Consequently, we
evaluated the effect of everolimus and/or sorafenib on
Figure 1 Immunohistochemical evaluation of the presence and amounts of P-ERM and P-mTOR in MPM samples. Representative fields of epitheloid
(A, C) and sarcomatous (B, D) tumor subtypes expressing P-mTOR (A, B) and P-ERM (C, D) are shown. P-mTOR is present in the cytoplasm of
malignant mesothelia clusters. P-ERM are diffusely and uniformly expressed on the membrane of neoplastic mesothelial cells.
Figure 2 Inhibition of mTOR and ERK1/2 MAPK pathways by sorafenib (S), everolimus (E) and their combination. A. representative western blot
images obtained with in MES-MM98 cells B. Histograms showing quantification of phosphorylated proteins after normalization with the respective
total proteins and the housekeeping (vinculin).
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slight increase in ERM phosphorylation after 24 h treat-
ment with everolimus, whereas sorafenib caused a sharp
decrease in ERM activation, both as a single agent and in
combination (Figure 3A). Since ERM proteins and in par-
ticular ezrin are involved in signalling and cell migration
in normal and cancerous cells [16] we evaluated the effect
of sorafenib and everolimus in scratch assay and CELLin-
gence migration test. We demonstrated that sorafenib and
everolimus alone and even more in combination inhibited
cell migration (p < 0.001, Figure 3B). To further elucidate
the role of ERM proteins in MPM cells, we down-regulated
the expression of its principal component, ezrin, by trans-
ducing H226 and MSTO-H211 with specific siRNA. After
48 and 72 h from silencing we observed a sharp reduction
in the expression of this protein, as evaluated by western
blot (Figure 4A). We demonstrated that the down-
regulation of ezrin slightly reduced cell viability after 24, 48,
72 hours (p < 0.001) and impinged on the migration ability
of MPM cells (Figure 4).
Sorafenib and everolimus exert synergistic effects on
MPM cell growth and viability
We then moved to investigate the biological readout of
the inhibition of specific signalling pathways by everolimusFigure 3 Sorafenib and everolimus effect on (A) ERM activation and (B) M
10nM, green line sorefenib 2.5 μM, and red line combination-treated cells.and sorafenib in MPM cell lines. We evaluated whether
sorafenib and everolimus influenced cell viability, by ex-
posing cultured MPM cell lines to increasing doses of
these two drugs, alone or in combination, for 72 hours. A
measurement of cellular ATP content by means of cellTi-
terGlo® assay demonstrated that sorafenib induced a dose-
dependent decrease in cell numbers in all tested MPM
lines. Treatment with everolimus alone resulted in a weak
effect, leading to a decrease in cell vitality from 20% to
30% at the highest tested dose (2 μM, Figure 5A). The
treatment with the combination resulted in a significantly
greater viability impairment compared to either agent
alone, displaying synergism in the interval of 30-70% of
fractions affected (CI < 1), as confirmed by a reduction of
the IC50 for both drugs (Table 1). We next evaluated the
capability of low doses of sorafenib, everolimus, and their
combination, to interfere with cell growth in vitro after
mid-long term culture. Figure 5C shows a representative
experiment performed with MES-MM98 cells. In these
assays, a 10 day-treatment with low-dose everolimus
(10 nM) was sufficient to significantly reduce the mean
colony area to 43 ± 6.8% of the control (p < 0.05). On the
contrary, sorafenib alone displayed a significant effect only
at 2.5 μM (35.2 ± 6.2% of the control. p < 0.05). A com-
bined treatment resulted in a potentiated dose–responseES-MM98 cell migration; black line untreated cells, blue line everolimus
Figure 4 Silencing of ezrin in MES-MM98 cells. A western blot analysis of ezrin protein expression. B. In vivo time course XCelligence analysis of
migrating H226 cells after 24 h from mock (control) and ezrin-specific siRNA treatment C. Wound healing assay with MPM cells after 72 hours
from treatment with control siRNA (siCTRL), and ezrin-specific siRNA (siEZRIN). The histogram depicts cell migration, calculated as percentage of
wound healing after 24 h from the scratch In the text: “We demonstrated that the down-regulation of ezrin slightly reduced cell viability after 24,
48, 72 hours (p < 0.001) and impinged on the migration ability of MPM cells (Figure 4 B,C,D).
Pignochino et al. BMC Cancer  (2015) 15:374 Page 6 of 13effect (62.8 ± 3.5% of the control with SOR 1.25 μM+EV
10 nM; 87.4 ± 4.9% of the control with SOR 2.5 μM+EV
10 nM, p < 0.05). The result obtained with the other MPM
cell lines are shown in Additional file 3: Figure S2.Everolimus potentiates the pro-apoptotic effect of sorafenib
in MPM cell lines
To investigate the mechanism(s) by which sorafenib and
everolimus influenced the viability and/or proliferation
Figure 5 Synergistic anti-proliferative effects of sorafenib and
everolimus on MES-MM98 cell lines, calculated according to the
number of viable cells in culture based on quantitation of the ATP
present. (A) Representative dose-effect curve of MES-MM98 cells
treated with scalar doses of sorafenib, everolimus or their combination.
The dose effect curve was calculated by CalcuSyn software after 72 h
of treatment. (B) Photograph of a representative colony growth of
MES-MM98 cells after 10 day-incubation in complete medium alone
(NT) or with sorafenib (SOR 2.5 μM), everolimus (EV 10 nM), or their
combination (SOR 2.5 μM+ EV 10 nM). (C) Analysis of the total surface
area occupied by colonies/well after treatment with escalating doses of
sorafenib (0, corresponding to control, 1.25 μM and 2.5 μM), alone or in
combination with everolimus (10 nM). *p < 0.05 vs NT; †, p < 0.05 vs
both single agents and control. Results are expressed as mean ± standard
deviation of triplicate experiments.
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by propidium iodide (PI) staining and cytofluorimetric
evaluation after 48 hours of combined drug treatment
(SOR 2.5 μM+ EV 10 nM). We observed a decreasedproportion of cells in the S and G2/M phase and an in-
creased proportion of cells in the G0/G1 fractions, as a
result of cell cycle arrest (Figure 6A). These analyses also
revealed an increased percentage of drug-treated cells
with sub-diploid DNA contents (32.61%) compared to
single treatments (21.03% sorafenib, 11.81% everolimus)
and control, vehicle-treated cells (5.6%). These data sug-
gested that sorafenib and everolimus induced apoptosis
in MPM cells. We therefore evaluated the percentage of
apoptotic MPM cells by Annexin-V staining coupled to
PI incorporation after 96 h from drug administration. As
shown in Figure 6B, treatment of MES-MM98 cells with
sorafenib alone (2.5 μM) significantly induced apoptosis
(67.31% Annexin V/PI positive cells vs 25.99% in vehicle
treated control cells). Everolimus alone had no effect on
the percentage of apoptotic cells (27.69% Annexin V/PI
positive cells). However, the combined drug treatment
resulted in potentiated effect (85.42% Annexin V/PI
positive cells), suggesting that everolimus enhanced
sorafenib-induced apoptosis of MPM cells.
Sorafenib and everolimus induce ROS production and
cJun/p38-mediated apoptosis in MPM cell lines
To dissect the molecular pathways driving the apoptotic
response in sorafenib- and everolimus-treated MES-
MM98 cells, we first evaluated the phosphorylation of
AMP-activated protein kinase (AMPK) on Thr172, an
event that has been related to cellular stress and to the
generation of mitochondrial ROS [20]. We observed that
AMPK phosphorylation is specifically increased as a
consequence of sorafenib treatment, both as a single
agent and in the combination schedule (Figure 6C). We
quantified ROS production by the use of a specific probe
(MitoSOX™), demonstrating by confocal analysis that the
percentage of positive cells dramatically increased in so-
rafenib (31.33 ± 4.3%) and combination-treated cells
(55.98 ± 6.1%) in comparison with everolimus- treated
cells (19.05 ± 2.7%) and untreated controls (16.22% ±
2.1%). These results were further confirmed by flow cy-
tometry, allowing a better quantification of the percent-
age of cells with more brilliant signals produced by ROS
and probe reactions (Figure 7). We also observed that,
following a 15-minute pre-treatment and a further incu-
bation in the presence of the ROS scavenger BHA, the
percentage of apoptotic cells was significantly reduced in
comparison to combination-treated cells (Figure 6B).
ROS have been traditionally viewed as generic cell-
damaging agents; however, they also function as specific
activators of key cellular processes, among which the
MAPK signal transduction cascades [21]. Indeed, the
stress-activated c-Jun and p38 MAPK have been impli-
cated in the apoptotic response to different signals, in-
cluding toxic chemical insults, environmental stress, and
oxidative stress. We therefore evaluated the activation of
Table 1 Drug concentration leading to a 50% inhibition of cell viability at 72 h (IC50) in cellTiterGLO® assay and
Combination Index (CI) for each cell line
MPM Cell
Lines
IC50 Drug alone (95% confidence interval) IC50 Drug combination (95% confidence interval) CI at IC50 ± Est. st.dev*
Everolimus (nM) Sorafenib (μM) Everolimus (nM) Sorafenib (μM)
MES-MM98 >100 4.21 (2.91-6.09) 40 (10.6-150.5) 2 (1.03-4.02) 0.485 ± 0.20
MM001 >100 2.01 (1.86-2.21) 23.6 (14.9-37.5) 1.18 (0.75-1.87) 0.585 ± 0.08
NCI-H226 >100 2.12 (1.55-2.89) 32 (20.5-49.9) 1.60 (1.02-2.49) 0.755 ± 0.23
MSTO-211H >100 0.90 (0.68-1.19) 34 (33.4-35.3) 0.17 (0.01-1.77) 0.426 ± 0.19
IST-MES1 >100 1.69 (1.10-2.60) 28.3 (17.1-46.8) 1.42 (0.85-2.34) 0.873 ± 0.30
IST-MES2 >100 2.16 (1.66-2.80) 19.1 (9.8-37.1) 0.96 (0.49-1.86) 0.573 ± 0.22
NCI-H28 >100 3.34 (2.27-4.92) 27 (14–51.6) 1.36 (0.71-2.58) 0.920 ± 0.34
NCI-H2052 >100 6.21 (4.45-8.66) 44.7 (31–63.9) 2.23 (1.56-3.19) 0.950 ± 0.21
MM002 >100 2.78 (2.30-3.35) 18.6 (6–57.2) 0.93 (0.30-2.86) 0.345 ± 0.12
*combination index calculated at IC50 ± estimated standard deviation based on Chou-Talalay method.
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sorafenib alone and in combination with everolimus
induced c-Jun and p38 activation (Figure 6C). This
activation was correlated with the increase of apoptosis
and ROS production mediated by these drugs (Figures 7B
and 6). The apoptotic status was confirmed by the increase
of PARP cleavage, the ultimate hallmark of apoptosis
(Figure 6C). Inhibition of p38 pathway with the selective
blocker SB202190 was paralleled by a reduction of
apoptotic cells upon sorafenib and everolimus treatment
confirming the role of p38 MAPK in sorafenib-everolimus
induced apoptosis (Figure 6D).
In vivo antitumor effects of sorafenib and everolimus on
human MPM xenograft models
Based on the results obtained by in vitro experiments,
we moved to assess a potential synergism of sorafenib
and everolimus on preclinical models of human MPM
obtained by subcutaneous injection of MPM cell lines in
immunocompromised mice. We orally administered so-
rafenib (5 mg/kg/die) and everolimus (1 mg/kg/die) for
4 weeks, observing that both drugs induced a significant
inhibition of tumour growth compared to the controls.
The combination treatment reduced tumor growth at a
higher extent, in comparison with both single drug alone
or vehicle-treated controls (p < 0.05, Figure 8A). This ef-
fect was associated to increased numbers of apoptotic
cells, as detected by TUNEL assay. The induction of
apoptosis was slight after treatment with single-agent
everolimus, significant after treatment with single-agent
sorafenib, and reached the maximum following a com-
bined therapy (Figure 8C). We finally evaluated the
organization of vessels and capillaries by staining for the
CD31 endothelial marker. This analysis revealed that
sorafenib induced a sharp reduction of microvessels;
conversely, everolimus was responsible of a weak impair-
ment of the tumoral vessel network. The combinationtreatment resulted in an almost complete depletion of
blood vessels into the tumoral area (Figure 8B). These data
demonstrated that a combination of everolimus and soraf-
enib induced tumor cell apoptosis and reduced tumor ves-
sels, thus proving to be a valuable therapeutic approach in
preclinical models of human MPM.
Discussion
MPM is an aggressive tumor with an ominous prognosis,
due to the unavailability of effective therapeutic regi-
mens. Albeit being considered a rare form of cancer, the
incidence of MPM is on the rise, due to worldwide ex-
posure to asbestos over the past decades. A better un-
derstanding of the molecular mechanisms involved in
MPM carcinogenesis is urgently needed to design suc-
cessful therapies that could offer MPM patients a real
clinical benefit. The activation of mTOR pathway is a
prognostic factor for MPM, in particular P-mTOR ex-
pression during induction chemotherapy was associated
with shorter overall survival [8]. Moreover, mTOR inhib-
ition has shown evidences of efficacy in MPM preclinical
models [22,23]. In the present work, we confirmed that
mTOR pathway is activated in MPM. With respect to
the histologic subtype, in contrast with a previous report
showing a prevalent mTOR expression in the epithelioid
forms [8], we observed that the presence of an activated
mTOR protein is unrelated to MPM histotypes. We fur-
ther report that the phosphorylation of mTOR is not a
consequence of the occurrence of somatic mutations in
upstream mediators, e.g., PIK3CA, KRAS, BRAF and
EGFR. These results suggest that, in MPM, the activa-
tion of mTOR signalling is triggered mainly by environ-
mental and/or metabolic factors, among which a direct
exposure to biopersistent fibers, such as asbestos [24].
We here demonstrated, for the first time to our know-
ledge, that pleural mesothelioma expresses activated
ERM, and that the expression of its principal component
Figure 6 (See legend on next page.)
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Figure 6 Mechanisms of apoptosis induction by sorafenib and everolimus combination. (A) Bar graph of cell cycle distribution in MES-MM98 cells
after 48 h treatment with sorafenib (2.5 μM), everolimus (10 nM) and their combination, compared to untreated control. (B) Induction of apoptosis in
MES-MM98 cells, in the absence (blue bars) or in the presence (red bars) of the ROS scavenger BHA. (C) Activation of AMPK by sorafenib treatment.
Everolimus potentiated the effect of sorafenib on AMPK activation, reflecting the enhancement of mTOR inhibition and the pro-apoptotic
effect of sorafenib and everolimus mediated by c-Jun and p38 activation, triggered by ROS production. PARP cleavage confirmed the apoptotic
status. (D) Propidium iodide and Annexin V staining of MES-MM98 cells treated with sorafenib (2.5 μM), everolimus 10 nM, and the p38 inhibitor
SB202190. These experiments are representative of 4 different tested cell lines
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of MPM cells. ERM proteins are cytoplasmic linkers be-
tween transmembrane proteins and the actin cytoskel-
eton with an active role in signal trasduction [11,12]. In
particular, ezrin has been reported as responsible for cell
survival signals transduced through the PI3K/AKT/
mTOR pathway [25]. In a previous study we obtained
ERM dephosphorylation by means of treatment with
multikinase inhibitor sorafenib in preclinical models of
osteosarcoma [17]. Based on these assumptions, we in-
vestigated whether a combined inhibition of mTOR
pathway and sorafenib treatment could provide an ef-
fective strategy for MPM management. Despite a gener-
ally low efficacy of everolimus as a single agent, we
reported a strong synergism of the two drugs in inhibit-
ing cell proliferation in vitro. The combined treatment
was capable to strongly induce apoptosis, by the induc-
tion of a ROS burst as we previously observed in sar-
coma cell lines [26]. Consistently, we observed that
sorafenib activates the energy sensor AMPK [27], furtherFigure 7 ROS production in MES-MM98 cells left untreated (control) or tre
24 h and then stained with the ROS-specific MitoSOX™ probe. (A) Confocal m
33342 bar = 10 μm. (B) Histograms of flow cytometry analysis.inducing mTOR pathway blockage. In the present work
with mesothelioma cells, we further characterized apop-
totic signalling induced by sorafenib and everolimus
treatment. We demonstrated that sorafenib as single
agent and even more in combination with everolimus in-
duced mitochondrial ROS production, being this event
related to apoptosis induction. Accordingly, treatment
with a ROS scavenger protected MPM cells from apop-
tosis. Moreover, we observed p38 MAPK and c-Jun activa-
tion upon sorafenib and everolimus treatment inferring
their specific role as downstream mediators of sorafenib
and everolimus-induced apoptosis. In fact, we demon-
strated that the inhibition with specific p38 chemical
inhibitor SB202190 protected MPM cells from sorafenib-
everolimus induced apoptosis. Again, according to previous
results obtained in sarcoma models [17], we demonstrated
that sorafenib was capable to inhibit also in MPM cells the
phosphorylation of ERM, both as a single agent and in
combination suggesting ERM as potential novel direct or
indirect therapeutic targets of this drug. On the contrary,ated with everolimus 10 nM, sorafenib 5 μM and their combination for
icroscopy photomicrographs. Nuclei are counterstained with Hoechst
Figure 8 In vivo antitumor effect in human MPM xenograft models. (A) After tumor establishment, 6 mice per group were randomized to daily
receive sorafenib 5 mg/kg/day, everolimus 1 mg/kg/day, their combination or vehicle alone. Tumor volume was monitored as described in the
“material and methods” section and is reported in graph as mean ± St. Dev (Y error bar). *, p < 0.05 vs vehicle alone; †, p < 0.05 vs either single
agent and vehicle alone. (B) Vascular specific CD31 staining and (C) TUNEL assay on vehicle (NT), everolimus 1 mg/kg/day (EV), sorafenib 5 mg/
kg/day (SOR), and combination (CB) treated xenografts.
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ministered as a single agent. We hypothesized that this
effect might be triggered by the activation of AKT
[19,28] that, in turn, phosphorylates the tumor suppres-
sor protein merlin [29]. In fact, this phosphorylation in-
duced the dissociation of merlin from the complex with
ezrin, moesin and CD44 allowing its switch toward an
activated growth-promoting form [30]. Being merlin an
interesting biomarker in MPM [31], reciprocal ezrin
and merlin coordination in MPM onset and their influ-
ence on response to drugs deserve further investiga-
tions. The mTOR pathway is involved in ezrin- induced
malignant phenotype [15], moreover the mTOR inhib-
ition has shown antitumor effect in mesothelioma pre-
clinical models [5,6,22,23]. To further investigate the
effect of combining sorafenib and everolimus treatment
in in vivo models of MPM, we set up MSTO-H211
xenografts into NOD/SCID mice. We observed thatlow doses of sorafenib and everolimus (physiologically
achievable in human plasma and capable of inducing sig-
nificant pharmacodynamic effect), as single agents and in
combination, significantly reduced tumor growth without
impairing the general health conditions of the treated
mice. At the end of the experiments, no sign of adverse
events was seen after necroscopy. Moreover, it will be im-
portant to investigate this treatment against tumors grown
orthotopically to obtain insights on the effect on specific
MPM microenvironment.
Conclusions
In conclusion, everolimus and sorafenib exert antitu-
mor activity in preclinical models of human MPM.
These results provide a rationale for further clinical in-
vestigations, encouraging the planning of phase II trials
with a combined sorafenib-everolimus schedule in MPM
patients.
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Additional file 1: Table S1. Clinico-pathological details for each
analyzed case. Histology. E denotes epithelioid forms, S denotes
sarcomatous forms, B denotes biphasic subtypes.
Additiona file 2: Figure S1. Correlation between outcome and mTOR
and ezrin activation. The level of protein activation is expressed
according the IHC staining. Data have been obtained through GraphPad
analysis.
Additional file 3: Figure S2. Clonogenic properties of treated cells.
Photograph of a representative colony growth of eight cell lines
treated after 10 day-incubation in complete medium alone (NT) or
with everolimus (EV 10 nM), sorafenib (SOR 1.25 μM), or their combination
(SOR 1.25 μM + EV 10 nM) I cannot be able to see the addictional files in
the proofs downloaded.
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